Sophiris Bio Overview
- Year Founded
-
2002
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
- Financing Rounds
-
12
- Investments
-
1
Sophiris Bio General Information
Description
Developer of biopharmaceutical therapies intended for the treatment of urological diseases and prostate conditions in the United States. The company develops targeted protein-based therapeutics, including topsalysin for localized prostate treatment, using selective activation mechanisms.
Contact Information
Website
www.sophirisbio.comCorporate Office
- CA 92037
- United States
Corporate Office
- CA 92037
- United States
Sophiris Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sophiris Bio Comparisons
Industry
Financing
Details
Sophiris Bio Competitors (1)
One of Sophiris Bio’s competitors is Viking Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Viking Therapeutics | Formerly VC-backed | San Diego, CA |
Sophiris Bio Patents
Sophiris Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017212734-A1 | A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer | Inactive | 27-Jan-2016 | ||
| CA-3012459-A1 | A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer | Inactive | 27-Jan-2016 | ||
| EP-3407906-A1 | A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer | Inactive | 27-Jan-2016 | ||
| EP-3407906-A4 | A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer | Inactive | 27-Jan-2016 | ||
| WO-2017132610-A1 | A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer | Inactive | 27-Jan-2016 | A61K38/17 |
Sophiris Bio Signals
Sophiris Bio Acquisitions (1)
Sophiris Bio’s most recent deal was a Merger/Acquisition with SNB Capital (Special Purpose Acquisition Company). The deal was made on 13-Jul-2004.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SNB Capital (Special Purpose Acquisition Company) | 13-Jul-2004 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Sophiris Bio FAQs
-
When was Sophiris Bio founded?
Sophiris Bio was founded in 2002.
-
Where is Sophiris Bio headquartered?
Sophiris Bio is headquartered in CA.
-
What is the size of Sophiris Bio?
Sophiris Bio has 6 total employees.
-
What industry is Sophiris Bio in?
Sophiris Bio’s primary industry is Drug Discovery.
-
Is Sophiris Bio a private or public company?
Sophiris Bio is a Private company.
-
What is Sophiris Bio’s current revenue?
The current revenue for Sophiris Bio is .
-
How much funding has Sophiris Bio raised over time?
Sophiris Bio has raised $163M.
-
Who are Sophiris Bio’s competitors?
Viking Therapeutics is a competitor of Sophiris Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process